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Lung cancers account for a huge percentage of death in industrialized countries, and hence there is an increasing call for the
development of novel treatments. These malignancies are caused by a combination of environmental factors, principally cigarette
smoking and genetic alterations. MicroRNAs (miRNAs) are a recently discovered class of regulatory noncoding small RNAs with
a signiﬁcance in numerous biological processes. Strong evidence links miRNA impaired expression proﬁles and pathways to the
etiology of several diseases, including neoplasia. This paper focuses on the emerging role of miRNA function in lung cancer
development with particular highlighting on the use of miRNA proﬁles and polymorphisms for the molecular and biological
characterization of tumor pulmonary growth and progression. Furthermore, we underline the potential utility of lung cancer-
associated miRNAs as clinical biomarkers with a diagnostic, prognostic, and therapeutic signiﬁcance and give emphasis to the
promising novel miRNA-based curative strategies.
1.Introduction
Lung cancer is one of the commonest neoplasia and the ﬁrst
cause of death worldwide, in both women and men, with an
increasing incidence rate. Less than 10% of people with the
disease live longer than ﬁve years after diagnosis [1, 2]. Lung
tumor is characterized by a preponderance of carcinoma
derived from changes and abnormally growth of epithelial
lung cells. Small cell lung carcinoma (SCLC) and non-
small cell lung carcinoma (NSCLC) are two main distinct
types of this neoplasia that have considerable diﬀerences in
pathogeneticmechanisms,cellularorigin,molecularchanges
and histopathological and clinical features [1]. Furthermore,
they show a diﬀerent response to therapeutic treatments
such as surgical resection, radiation, and chemotherapy.
NSCLCcomprisesapproximately80%ofalllungcancersand
can be classiﬁed into adenocarcinoma (AC), squamous cell
carcinoma (SqCC), and large cell carcinoma, whereas SCLC
tendstospreadmorequicklythanNSCLCandcanbedivided
into small cell carcinoma (SCC), mixed small cell/large cell
carcinoma, and combined small cell carcinoma. Symptoms
can be absent or very moderate, mainly in the early stages of
tumor transformation, so that a large percentage of patients
is diagnosed only in advanced stage of tumor extension with
a consequent poor treatment outcome. Although surgery
provides a potential curative strategy, patients often develop
recurrence with a survival rate that remains very low espe-
cially in subjects with metastatic disease. Therefore, looking
for biomarkers able to accurately detect early tumor changes
is the principle warrant in lung cancer management [3].
Diﬀerent factors have been associated with an increased risk
of lung cancer development, mainly cigarette smoke and air-
carcinogens, as well as a family history of pulmonary tumor.
Lung neoplasia has indeed a multifactorial etiology being
caused by gene-gene and gene-environment interactions [4,
5]. The importance of genetic background in lung tumor
has been well highlighted and, in recent years, microRNA-
(miRNA or miR) speciﬁc signatures have been reported to
play a critical role in cancer transformation. These molecules
represent a novel potential class of sensitive markers for
diﬀerent and signiﬁcant clinical applications.2 Pathology Research International
2. MicroRNA Overview
MicroRNAs are evolutionarily conserved small noncoding
RNAs that negatively regulate gene expression at the post-
transcriptional level by repressing translation or decreasing
mRNA stability [6, 7]. MiRNAs are initially transcribed by
RN ApolymeraseIIaslongprimarymolecules(pri-miRN A s)
that are processed in the nucleus into hairpin precursors
(pre-miRNAs) via the RNase-III enzyme DROSHA and the
RNA-binding protein DGCR8 [8]. Pre-miRNAs are further
transported to the cytoplasm by RAN GTPase/Exportin 5
complex where they are matured into active miRNAs by
RNase III enzyme Dicer [9]. Mature miRNA, a single-
strandedRNAwithalengthofabout22nucleotides,isincor-
porated into an RNA-induced silencing complex (RISC)
by RNA processing proteins, such as AGO1 and AGO2
[10]; miRNA is now able to bind target transcripts through
base pairing with their 3 -untranslated regions (UTRs). The
sequence important for mRNA recognition encompasses
bases 2 to 8 at the 5 -end of the mature miRNA, and it is
known as the “seed sequence” [6].
To date, more than 800 miRNAs have been identiﬁed
in the human genome [11], each of them having the
potential capacity to bind to hundreds of transcripts, and the
biological functions of most miRNAs are rapidly emerging.
As estimated by in silico prediction algorithms [11, 12],
miRNAs regulate at least 30% of the protein-encoding genes
and are involved in a broad range of cellular processes such
as proliferation, diﬀerentiation, homeostasis, and apoptosis,
so it is not strange that the dysregulation into the miRNA
pathway might contribute to human diseases, including
cancer development. Distinct patterns of miRNA expression
share common pathways and display a signiﬁcant tumor
speciﬁcity supporting their use as promising clinical and
biological markers for diﬀerent cancer aspects as formation,
progression, diagnosis, prognosis, and response to therapy
[13–17].
2.1. MiR-Proﬁling in Lung Cancer. Since their discovery,
increasing evidence indicates a deep involvement of miRNAs
in human lung tumorigenesis by acting as tumor suppres-
sors or oncogenes, largely by targeting proteins that are
key regulators of cellular proliferation and survival, DNA
repair, and immune response [18]. Expression of speciﬁc
microRNAs is substantially changed in a number of diﬀerent
lung cancer types compared to nontumor lung tissues and
cells [19, 20]. Furthermore, many of these miRNAs are
located at chromosome regions which are frequently deleted
or ampliﬁed in several malignancies [13, 21]. Let-7 was the
ﬁrst microRNA reported to have a role in lung cancer devel-
opment[22].Reducedlevelsoflet-7 miRNAfamilymembers
were found both in vitro and in vivo studies of human
pulmonaryneoplasia,andlet-7-mediatedtumorsuppression
was suggested to occur largely through the regulation of
HMGA2 and RAS genes associated with cell division [20, 22–
24];miR-126 expressionindiﬀerentlungtumorcelllineswas
inversetotheupregulatedVEGF whichresultedtobeadirect
target of miR-126 [25]. Chen et al. [26] showed that miR-145
amountwasmarkedlydecreasedinNSCLCtumorspecimens
and in two human NSCLC cell lines, A549 and H23, relative
to nonmalignant lung tissues and cells, respectively. MiR-
145 has been shown to act as an antioncogenic molecule
able to inhibit proliferation and the G1/S transition of
lung cancer cells by aﬀecting c-Myc/eIF4E4/CDK4 protein
levels without changes in apoptosis [27]. Dysregulation of
miR-451 correlated with the development of non-small cell
lung cancer by enhancing apoptosis probably through the
inactivation of Akt signaling pathway [28]. In particular,
downregulation of miR-451 was signiﬁcantly associated
with strong positive immunoreactivity of RAB14 protein, a
member of RAS oncogene family. Although the majority of
miRNAshavebeenproposedtooperateastumorsuppressors
in lung cancer, as suggested by their overall downregulation,
an increasing number of miRNAs have been found to have
oncogenic properties. Overexpression of miR-17-92, miR-
31, miR-21,a n dmiR-7 signiﬁcantly enhanced proliferation
and tumorigenicity of lung cancer cells largely by inhibiting
negative regulators of oncogenic pathways [20, 29–32].
Moreover,miRNAexpressionsignaturesstrictlycorrelate
with tumor development and progression, also at an early
stage, and give signiﬁcant improvement in the molecular
characterizationandbiologicalclassiﬁcationofawidevariety
of human cancers, including lung malignancy [15, 33, 34].
For example, Yanaihara et al. [19] showed that a subset
of miRNAs was diﬀerently expressed in adenocarcinomas
and squamous cell carcinomas, with miR-99b and miR-102
showinghigherlevelsinACs.OverexpressionofmiR-205was
only detected in SqCCs but not in ACs, and an accurate dis-
tinction of the two NSCLC types was allowed by monitoring
its levels just in the early phases of cancer transformation
[35]. It has been speculated that the use of microRNAs
as tumor stage markers might also avoid the variability
in the pulmonary cancer subclassiﬁcation observed with
the conventional histopathologic and immunohistochemical
techniques due to quality/quantity limitations of bioptic
material and staining interpretation [15, 33, 36, 37]. The
deﬁnition of lung carcinoma subclasses with respect to
miRNA quantiﬁcation is extremely sensitive and speciﬁc
owing the high stability of miRNAs even in poorly conserved
specimens and to the advanced technologies used for their
detection as Real-Time PCR and Microarray [15].
MiRNA proﬁling was also linked to clinicopathological
tumor features and lung cancer patient outcome, thus
havingapotentialdiagnosticandprognosticimpact[38–40].
Downregulation of miR-125a-3p and miR-125a-5p in non-
small cell lung carcinomas predicted a more aggressive clin-
ical course by promoting tumor invasion and lymph node
metastasis [41]. Low levels of let-7a-2 in combination with
speciﬁc expression changes in other microRNAs associated
with poor survival in patients with lung adenocarcinoma
[19, 38]. The expression level of miR-451 was found to be
signiﬁcantly associated with NSCLC tumor diﬀerentiation,
pathological stage, lymph node metastasis, and shorter
o v e r a l ls u r v i v a lo fp a t i e n t s[ 28]. Elevated levels of miR-21,
miR-17,a n dmiR-155 were associated with cancer-speciﬁc
mortality and disease-free survival in NSCLC patients from
Maryland, Norway, and Japan [42]. In particular, increased
miR-21 expression was found in advanced stage tumors in allPathology Research International 3
thethreediﬀerentcohortssupportingitsprognosticvaluefor
lungadenocarcinoma.ArecentworkbyAroraetal.[43]ga v e
evidence of the importance to test the expression of miR-
328 in NSCLC samples since it correctly classiﬁed patients at
higherriskfordevelopingbrainmetastasis.Moreover,several
linesofevidencesuggestthatmicroRNAderegulationinlung
tumors may also predict disease recurrence and/or response
to adjuvant anticancer treatments, such as curative surgery,
chemotherapy, and radiotherapy [44, 45]. Downregulation
of microRNA-128b, due to loss of heterozygosity of 3p22
in lung tumor specimens, was associated to increased
epidermal growth factor receptor (EGFR) expression with a
consequent survival beneﬁt in patients treated with geﬁtinib,
a EGFR-tyrosine kinase inhibitor drug commonly used in
advanced NSCLC management [13]. High levels of miR-92a-
2∗ correlated with chemoresistance and decreased survival
of SCLC cases [46], whereas let-7 family of miRNAs could
augment sensibility to radiation in lung cancer cells [47].
Furthermore, reduced expression of let-7 in NSCLC tissues
was indicative of elevated postoperative risk of death of
the surgically treated patients [22]. Taken together, all
these observations suggest that the evaluation of expression
changes just in a subset of miRNAs might give impor-
tant information of practical use in clinical trials for the
management of lung oncologic patients since eﬃcacy of
therapeutic treatments mainly depends on accurate and
early tumor deﬁnition [3]. Moreover, microRNA proﬁling
results to have a predictive, diagnostic, and prognostic
application that can avoid the use of aggressive tools, such
as computed tomography, in lung tumor detection and
management [48]. The presence of stably expressed and
quantiﬁable miRNA levels in human serum, which are able
to discriminate between normal and lung cancer samples,
is an exciting discovery that strengthens the use of these
small regulatory molecules as novel noninvasive biomarkers
in lung cancer [49–51]. In particular, serum miRNA detec-
tion might have the advantage to early select patients for
appropriate treatment strategies in order to enhance their
survival chance. However, results obtained among diﬀerent
studies suggest that circulating miRNA quantiﬁcation needs
accurate standardization before the potential as a screening
tool in the management of lung cancer may be realized.
In this regard, an important goal was obtained by Yu et
al. [52] that developed a highly sensitive and speciﬁc panel
of miRNAs for the early detection of lung adenocarcinoma
in sputum. In particular, miR-21, miR-486, miR-375,a n d
miR-200b showed a signiﬁcantly diﬀerent expression in lung
adenocarcinoma patients versus normal subjects and their
combinedvalueswereabletodistinguishaﬀectedindividuals
from healthy controls with 80.6% sensitivity and 91.7%
speciﬁcity in independent populations.
2.2. MiR-Polymorphisms and Lung Tumor Susceptibility. New
ﬁndings have shown that alterations of miRNA expression
or activity in cancers can be due to sequence variations in
miRNAgeneregions,ingenesinvolvedinmiRNAbiosynthe-
sis or at binding sites in the 3 -UTR of miRNA target genes,
collectively referred to as “miR-polymorphisms” [17, 53–
55]. Single-nucleotide polymorphisms (SNPs) might indeed
aﬀect miRNA primary transcript formation and expres-
sion, miRNA processing and maturation, and/or miRNA-
target interactions. The role of polymorphisms in miRNA
sequences and in genes involved into miRNA biogenesis
is rapidly emerging and several studies have demonstrated
their role in a wide spectrum of malignancies, including
lung cancer [54–59]. In particular, miRNA genetic variants
might have a potential clinical utility being predictors of
lung tumor predisposition. The rs11614913T>C SNP in the
miRNA-196a2sequenceincreasedmaturemiRNAexpression
and target binding activity. Moreover, case-control studies in
diﬀerent ethnic populations showed that the CC genotype
was signiﬁcantly associated to an increased risk of lung
cancer, particularly SqCC type, and predicted a reduced
patient survival [56, 60]. Kim et al. [61] found that AGO1
rs636832A>G could modulate susceptibility to lung neopla-
sia since both the heterozygotes and homozygotes for the
G allele had a decreased risk of lung cancer compared with
subjects carrying the AA genotype. The genetic variation
rs712T>G in a let-7 miRNA binding site in the 3 -UTR
of K-RAS transcript was found to signiﬁcantly increase
the risk of NSCLC, especially by stratifying individuals
for smoking history, through the oncogene upregulation
[62]. Additional replication studies in other populations
and in vitro experiments for the characterization of the
biological signiﬁcance of these particular SNPs are required
to validate these ﬁndings. Nevertheless, screening for miR-
polymorphisms could lead to better deﬁne the genetic risk
to lung carcinogenesis as well as its recurrence development.
For instance, miR-SNP genotypes and/or haplotypes might
allow to categorize lung tumor patients into low, medium,
and high-risk groups of disease with respect to determinate
clinical aspects, such as cancer progression, chance of sur-
vival, and response to therapies. Combinations of various
unfavorable SNPs could more accurately identify the risk of
cancer for each individual. In a recent work, Rotunno et al.
[63]showedthattheGTAATChaplotypeinRNASEN,coding
forDrosha,connectedwithlung cancer-speciﬁcreducedsur-
vival; moreover, a variant allele of rs640831 was signiﬁcantly
associated with RNASEN reduced mRNA expression and
with changes in the levels of particular microRNAs only in
adenocarcinomas but not in SqCC samples.
Hence, the potential prognostic implications of micro-
RNA-related genetic variations in lung cancer may be used
for developing novel personalized therapeutic applications
and for checking patient outcome.
2.3. MiR-Based Therapies in Lung Cancer. The accumulated
data on miRNA role as oncogenes or tumor suppressors in
lung carcinogenesis suggest that miR-based applications in
cancer medicine are an attractive and promising area for
patient cure. Indeed, if aberrant microRNA levels are found
into tumor tissues, restoring speciﬁc microRNA expression
might have therapeutic implications. Recent research activ-
ities have been focused on the discovery of new molecules
able to selectively and stably interfere with microRNA
regulatory networks and on the evaluation of the eﬃcacy,
stability, tolerability, and cost of the miR-based therapeutic
agents. In this context, therapies for knocking down speciﬁc4 Pathology Research International
Table 1: Lung cancer-related microRNAs.
MicroRNA Expression Target/Function Clinical value
let-7 family Down HMGA2, RAS, Myc, cell division
Associated with cancer-speciﬁc mortality and disease-free
survival; increased sensibility to radiation; elevated
postoperative risk of death; rs712GG genotype in K-RAS
3 -UTR associated with increased risk of NSCLC
let-7a-2 Down — Poor survival in AC patients
miR-17 Up cell proliferation Associated with tumor stage, cancer-speciﬁc mortality, and
disease-free survival in NSCLC
miR-102 Up — Higher levels in AC than in SqCC
miR-125a-3p/5p Down — Associated with tumor invasion and lymph node metastasis
miR-126 Down VEGF —
miR-128b Down EGFR Beneﬁt in patients treated with geﬁtinib
miR-145 Down c-Myc, eIF4E4, CDK4 —
miR-155 Up — Associated with tumor stage, cancer-speciﬁc mortality, and
disease-free survival in NSCLC
miR-196a2 Up — rs11614913CC genotype associated with increased risk of
lung cancer and reduced overall survival
miR-20b Down — Associated with advanced stages and lymph node metastasis
miR-21 Down K-RAS, cell proliferation
Associated with tumor stage, cancer-speciﬁc mortality, and
disease-free survival in NSCLC; able to discriminate lung
cancer from healthy controls
miR-29s Down DNMT3A, DNMT3B —
miR-205 Up — Only detected in SqCC
miR-31 Up LATS2, PPP2R2A,c e l l
proliferation —
miR-328 Up cell migration Associated with higher risk of brain metastasis development
Associated with overall survival
miR-451 Down RAB14,a p o p t o s i s Associated with NSCLC stage, lymph node metastasis, and
poor survival
miR-7 Up Ets2, cell proliferation —
miR-92a-2∗ Up — Chemoresistance and decreased survival of SCLC cases
miR-99b Up — Higher levels in AC than in SqCC
NSCLC: non-small cell lung carcinoma; AC: adenocaercinoma; SqCC: squamous cell carcinoma.
miRNAs with oncogenic activity are potentially based on
antisense miRNA modiﬁed-oligonucleotides, also known as
antagomirs, miRNA sponges, miRNA masking, and small
moleculeinhibitors,whilemiRNAmimicsmightbeusefulin
the reintroduction of miRNAs with tumor suppressor capa-
bility [14, 64, 65]. Experimental and preclinical data demon-
strated that the restoration of cancer-related microRNA
e x p r e s s i o nc h a n g e st on o r m a ll e v e l sb ym i R N Am i m i c so r
antagomirs could reverse the cancer phenotype in tumor
cells and in animal models of human neoplasia [66, 67].
In particular, mice intranasally inoculated with adenovirus
expressing let-7a microRNA showed decreased pulmonary
tumor formation in comparison to animals treated with
a scrambled sequence [68]. Indication that replacement of
let-7 family members may eﬀectively interfere with lung
carcinogenesisinvivowasalsoconﬁrmedbyarecentstudyby
Trangetal.[69]inwhichlet-7intranasalinjectionofmiceled
to reduced tumor lung size. Liposomal delivery of chemically
synthesized miR-34a in mouse models of NSCLC was specif-
ically able to restore microRNA expression, to silence down-
stream targets, and to inhibit lung tumor growth without
inducing an immune response, a pivotal characteristic for a
clinical application in tumor patient treatment [70]. Despite
thesepositiveresults,severallimitationsneedtobeovercome
before miRNA-based approaches might be successfully used
in human lung cancer treatment either alone or in combi-
nation with conventional therapies. Continuous studies are
strongly required in order to increase miRNAs speciﬁc and
eﬃcient tissue delivery, to improve microRNA stability, to
keep constant their activity, and to prevent oﬀ-target eﬀects,
immune stimulation, and toxicity. To this regard, nonviral
nanoparticle-based gene/RNA-delivery vectors seem to be
a promising system for an eﬃcient miRNA cellular uptake
[71]. An eﬃcient transport and delivery was obtained by
encapsulating microRNAs into high-density lipoproteins
or cationic liposomes [72, 73]. Ligands or monoclonal
antibodies that recognize tumor-speciﬁc receptors could
be conjugated to mimics/antagomirs in order to target
miRNAs at the disease site selectively [74, 75]. Strategies
for preventing nuclease degradation and increasing miRNA
half life are essentially linked to chemical modiﬁcations
of the RNA backbone such as 2 -ﬂuoro/2 -methoxyethyl
groups, phosphorothioate bonds, and nucleobases [76, 77].
In addition, an extremely precise deﬁnition of the speciﬁcPathology Research International 5
miRNA levels and molecular mechanisms in the diﬀerent
lung cancer types and subtypes is necessary to identify novel
targets which might be used for the development of new
therapeutic strategies. In this context, interesting studies
have demonstrated that DNMT3A and DNMT3B, two DNA
methyltransferases involved in epigenetic cellular control,
were direct targets of miR-29s and their over-expression
inversely correlated with miR-29s levels in NSCLC, suggest-
ing that drugs able to normalize DNA methylation patterns
might be used in clinical trials as lung anticancer agents
[78, 79].
3. Conclusions
Lung cancer is one of the main causes of cancer-related
deaths in industrialized countries with only 15% of all
patients surviving ﬁve years or more. Surgical resection of
tumor tissues is the only actual chance of life, together with
chemotherapy and/or radiotherapy for some individuals.
MicroRNAs are a class of endogenous small regulatory RNAs
that negatively control gene expression at the posttran-
scriptional level. Impaired expression of speciﬁc miRNAs
has been associated with lung cancer pathogenesis in sev-
eral studies and microRNA proﬁles might serve as novel
biomarkers to predict cancer progression, prognosis, genetic
risk, recurrence, and drug sensitivity (Table 1). Ameliorating
the acknowledgements of speciﬁc miRNA regulators, tumor
functions, downstream targets, and signaling pathways in
lung cancer is essential for elucidating complex regulatory
networks that are critical for the malignancy biology. These
ﬁndings will have to be focused on the development of
novel preventive and curative treatments. MiRNA mimics or
antisense oligonucleotides are indeed promising new tools
for cancer therapy.
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